Abstract:Objective To compare the efficacy and safety of pemetrexed combined with nedaplatin with pemetrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer(NSCLC). Methods Sixty cases of advanced NSCLC patients from October 2011 to October 2013 were select as study objects. All patients were randomly divided into two groups (30 cases each) through the lottery method. The observation group received pemetrexed combined with nedaplatin therapy (intravenous infusion of pemetrexed 500 mg/m² and nedaplatin 75 mg/m², supplemented by oral folic acid, dexamethasone, intramuscular injection of vitamin B-12, pay attention to the hydration). The control group received pemetrexed combined with cisplatin therapy (the dose and method of pemetrexed was same as observation group, combined with intravenous infusion of cisplatin 75 mg/m², supplemented with mannitol, potassium chloride, normal saline, and fully hydrated). Both groups were treated with 4 to 6 cycles (3 weeks a cycle). The progression free survival (PFS) and 2-year survival rate were recorded in the two groups, and the adverse reactions and quality of life were compared between the two groups. Results After 4 cycles of treatment the PFS of observation group was longer than control group ［(7. 52±1. 47) m vs (5. 01±0.91) m, P＜0.01］, but there was no statistical difference between two groups in the 2-year survival(36. 67% vs 16. 67%, P>0.05). Before and after the treatment, there was no significant change in observation group′s quality of life (P>0.05); While in the control group, quality of life score was lower than pretreatment(P<0.01), and the score was lower than observation group at the same period in the treatment (P<0.05, P<0.01). The incidence of adverse reactions (such as anemia, alopecia, and platelet descend) was significantly lower in the observation group than in the control group (P<0.05, P<0.01). Conclusion In the treatment for advanced NSCLC, pemetrexed combined with nedaplatin could have a better curative effect than combined with cisplatin, which could prolong PFS significantly and help to improve patient′s survival time. While it has fewer adverse reactions and higher safety, which have no significant effect on the quality of life of patients.